CardieX Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDX.AX research report →
Price Chart
About the company
CardieX Limited, established in Sydney, Australia, in 1994, is a global innovator specializing in the design, production, and distribution of medical devices for cardiovascular health management. Operating across the Americas, Europe, and the Asia Pacific, the company collaborates with pharmaceutical firms by providing its advanced SphygmoCor XCEL devices. It also delivers comprehensive laboratory and data management services, ensuring high-quality datasets for clinical trial sponsors.
- CEO
- Craig R. Cooper BEC,
- IPO
- 2005
- Employees
- 26
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on CDX.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.80M
- P/E
- -0.97
- Fwd P/E
- 0.56
- PEG
- 0.01
- P/S
- 3.15
- P/B
- 2.28
- EV/EBITDA
- -1.79
- Div Yield
- 0.00%
- Gross Margin
- 78.27%
- Op Margin
- -187.45%
- Net Margin
- -210.51%
- ROE
- -273.06%
- ROIC
- -126.67%
Latest fiscal year · YoY change
- Revenue
- $6.28M-42.4%
- Gross Profit
- $4.92M-51.3%
- Op Income
- $-11,776,969
- Net Income
- $-13,225,635-95.5%
- EPS
- $-0.04-9.7%
- OCF Growth
- -41.1%
- FCF Growth
- -39.3%
- 52W High
- $0.17
- 52W Low
- $0.03
- 50D MA
- $0.03
- 200D MA
- $0.07
- Beta
- 0.85
- RSI (14)
- 38
- Avg Volume
- 458.21K
No earnings-call transcripts are available for CDX.AX yet.
- Free Float
- 89.7%
- Shares Outstanding
- 550.08M
- Float Shares
- 493.42M
Our CDX.AX coverage
Recent articles, reports, and earnings notes.
No research on CDX.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CDX.AX report →